Johnson & Johnson subsidiary Centocor, Inc. received extended approval from the FDA for Remicade for inhibiting progression of structural damage and improving physical function in patients with psoriatic arthritis, in addition to reducing signs and symptoms of active arthritis. The approval is based on one-year data from the double-blind, placebo-controlled IMPACT 2 trial and two-year data from the IMPACT trial. Findings showed that at week 24, Remicade-treated patients had less structural d...